Dr. Eric J. Feldman, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 27
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 153850 -
Internal Medicine Physician
NY license 153850
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Montefiore Medical Center Bronx, NY
Medical groups
- Montefiore Medical Center (2,820 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 27
- Services billed
- 151
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 59 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Valacyclovir (valacyclovir hcl) Other prescribers in New York, NY | 16 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in New York, NY | 14 |
| Tramadol Hcl Other prescribers in New York, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $4,422 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $4,375 |
|---|---|
| AbbVie Inc. | $27.01 |
| Janssen Biotech, Inc. | $19.96 |
| Consulting Fee | $4,375 |
|---|---|
| Food and Beverage | $46.97 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 3, 2025 | Consulting Fee SCEMBLIX · Oncology | $2,275 |
| Novartis Pharmaceuticals Corporation Jun 30, 2025 | Consulting Fee SCEMBLIX · Oncology | $2,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $24,769 in research payments for these studies, mostly to the institutions running them.
- A phase 1B/2 study of TAK-981 plus pembrolizumab to evaluate the safety, tolerability, and antitumor activity of the combination in patients with select advanced or metastatic solid tumors
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.